Clinical Trials Using PBN Derivative OKN-007

Clinical trials are research studies that involve people. The clinical trials on this list are studying PBN Derivative OKN-007. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • OKN-007 and Temozolomide in Treating Patients with Grade III-IV Glioblastoma Multiforme Undergoing Adjuvant Concomitant Radiotherapy

    This early phase I trial studies the side effects of OKN-007 and temozolomide in treating patients with grade III-IV glioblastoma multiforme undergoing concomitant radiotherapy after surgery. OKN-007 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving OKN-007 and temozolomide chemo-radiotherapy may work better in treating patients with glioblastoma multiforme after surgery.
    Location: Stephenson Cancer Center, Oklahoma City, Oklahoma

  • Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

    This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients. All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater) established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
    Location: See Clinical